Wedbush Maintains Neutral on Alto Neuroscience, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 71.2%

Neg 71.2% Neu 0% Pos 0%

Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and lowers the price target from $22 to $21.